Challenges and Developments in Digital Health Companies and Direct-to-Consumer Marketing

The chapter delves into the obstacles faced by digital health companies going public through SPACs, the introduction of Pfizer's direct-to-consumer marketing platform, and new FTC regulations for medication advertising. It also discusses the launch of Lilly, declining fertility rates, and the impact of direct-to-consumer marketing on patients' perception of drug prices.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app